20/20 Biolabs, Inc. Common Stock (AIDX) — Cash Flow Reinvestment Rate
20/20 Biolabs, Inc. Common Stock (AIDX) has a Cash Flow Reinvestment Rate of 0.05x as of December 2022, reinvesting $261.79K (capex $261.79K ) from operating cash flow of $5.80 Million. Check how high is 20/20 Biolabs, Inc. Common Stock's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
20/20 Biolabs, Inc. Common Stock Cash Flow Reinvestment Rate (2022–2022)
Historical reinvestment intensity for 20/20 Biolabs, Inc. Common Stock across 1 annual periods. Explore how well can 20/20 Biolabs, Inc. Common Stock service its debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for 20/20 Biolabs, Inc. Common Stock (2022–2022)
Year-by-year capital reinvestment analysis for 20/20 Biolabs, Inc. Common Stock. For live market cap and broader valuation context, see how much is 20/20 Biolabs, Inc. Common Stock worth.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.05x | $261.79K | $5.80 Million | $261.79K | — |